jnj-64304500
mAbexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01203631)
Timeline
Indications
Mechanism of action
KLRK1 inhibitor
- GTP-binding protein GEMINHIBITOR
GEM inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- iph 2301
- jnj-64304500
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04712006 | Phase 1 | May 30, 2021 | Janssen Pharmaceutica NV |
| NCT04740970 | Phase 2 | Mar 24, 2021 | Janssen Pharmaceutica NV |
| NCT04655807 | Phase 2 | Jan 4, 2021 | Janssen Pharmaceutica NV |
| NCT04667052 | Phase 1 | Dec 16, 2020 | Janssen Pharmaceutica NV |
| NCT03002025 | Phase 1 | Jan 10, 2017 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02877134 | Phase 2 | Aug 25, 2016 | Johnson and Johnson |
| NCT01203631 | Phase 2 | Feb 1, 2011 | Johnson and Johnson, Novo Nordisk |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 5 | 4 | 2 | 2017 |
| Johnson and Johnson | For profit | 3 | 3 | 2 | 2011 |
| Novo Nordisk | For profit | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1